摘要
目的:对比观察阿德福韦酯与干扰素-α对慢性乙型肝炎患者谷丙转氨酶(ALT)复常率、乙型肝炎病毒DNA(HBV-DNA)阴转率及乙型肝炎E抗原(HBe Ag)阴转率的影响效果。方法:选取64例慢性乙型肝炎患者,随机将其分为观察组和对照组,每组32例。对照组患者采用干扰素-α治疗;观察组患者采用阿德福韦酯治疗,比较两组患者治疗后的肝功能指标,各时段肝功复常率、HBV-DNA阴转率、HBe Ag阴转率及不良反应发生率。结果:两组患者治疗后的谷草转氨酶(AST)、ALT及总胆红素(TBIL)肝功能指标均较治疗前明显改善,差异有统计学意义(t=0.7012,t=0.2058,t=0.1702;P<0.05)。两组患者在肝功复常率、HBV-DNA阴转率及HBe Ag阴转率方面相比无统计学差异。观察组患者不良反应发生率为3.1%,对照组患者不良反应发生率为18.8%,观察组明显低于对照组,两组相比差异有统计学意义(x2=4.010,P<0.05)。结论:阿德福韦酯治疗慢性乙型肝炎具有与干扰素-α相当的临床疗效,同时能降低不良反应发生率,治疗效果较为安全可靠。
Objective： To compare the effect of interferon-α and adefovir dipivoxi in affecting the results of chronic hepatitis B patients with ALT normalization rate, HBV DNA negative conversion rate and HBe Ag loss rate. Methods： Sixty four patients with chronic hepatitis B were selected from February 2012 to June 2014 in our hospital,randomly equally divided into the observation group and control group, the observation group patients using interferon therapy mainly, the control group patients mainly using adefovir dipivoxi treatment, to compare liver function before and after treatment, liver function recovery rate, HBV DNA negative rate, HBe Ag seroconversion rate at different times and incidence of adverse reactions. Results： Incidence of adverse reactions in observation group was significantly lower than that（3.1%） in the control group, the incidence of adverse reactions of 18.8%; Meanwhile, liver function after treatment of two groups improved significantly than before treatment（t=0.7012, t=0.2058, t=0.1702; P〈0.05）; liver function recovery rate, HBV DNA negative rate, HBe Ag seroconversion rates of two groups were not statistically different（x2=4.010, P〈0.05）. Conclusion： Adefovir dipivoxil treating patients with chronic hepatitis B has considerable clinical efficacy as interferon-α while reducing the incidence of adverse reactions, more secure and reliable.
出处
《中国医学装备》
2015年第11期105-108,共4页
China Medical Equipment
